Literature DB >> 21784434

Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis.

Micah J Eimer1, Wendy J Brickman, Roopa Seshadri, Rosalind Ramsey-Goldman, David D McPherson, Beverly Smulevitz, Neil J Stone, Lauren M Pachman.   

Abstract

OBJECTIVE: A pilot study of adults who had onset of juvenile dermatomyositis (JDM) in childhood, before current therapeutic approaches, to characterize JDM symptoms and subclinical cardiovascular disease. STUDY
DESIGN: Eight adults who had JDM assessed for disease activity and 8 healthy adults (cardiovascular disease controls) were tested for carotid intima media thickness and brachial arterial reactivity. Adults who had JDM and 16 age-, sex-, and body mass index-matched healthy metabolic controls were evaluated for body composition, blood pressure, fasting glucose, lipids, insulin resistance, leptin, adiponectin, proinflammatory oxidized high-density lipoprotein (HDL), and nail-fold capillary end row loops.
RESULTS: Adults with a history of JDM, median age 38 years (24-44 years) enrolled a median 29 years (9-38 years) after disease onset, had elevated disease activity scores, skin (7/8), muscle (4/8), and creatine phosphokinase (2/8). Compared with cardiovascular disease controls, adults who had JDM were younger, had lower body mass index and HDL cholesterol (P = .002), and increased intima media thickness (P = .015) and their brachial arterial reactivity suggested impairment of endothelial cell function. Compared with metabolic controls, adults who had JDM had higher systolic and diastolic blood pressure, P = .048, P = .002, respectively; lower adiponectin (P = .03); less upper arm fat (P = .008); HDL associated with end row loops loss (r = -0.838, P = .009); and increased proinflammatory oxidized HDL (P = .0037).
CONCLUSION: Adults who had JDM, 29 years after disease onset, had progressive disease and increased cardiovascular risk factors.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784434      PMCID: PMC3193560          DOI: 10.1016/j.jpeds.2011.05.015

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  27 in total

Review 1.  The role of neopterin in atherogenesis and cardiovascular risk assessment.

Authors:  D Fuchs; P Avanzas; R Arroyo-Espliguero; M Jenny; L Consuegra-Sanchez; J C Kaski
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 2.  Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.

Authors:  Brian M Feldman; Lisa G Rider; Ann M Reed; Lauren M Pachman
Journal:  Lancet       Date:  2008-06-28       Impact factor: 79.321

3.  Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.

Authors:  Laura E Schanberg; Christy Sandborg; Huiman X Barnhart; Stacy P Ardoin; Eric Yow; Gregory W Evans; Kelly L Mieszkalski; Norman T Ilowite; Anne Eberhard; Deborah M Levy; Yukiko Kimura; Emily von Scheven; Earl Silverman; Suzanne L Bowyer; Lynn Punaro; Nora G Singer; David D Sherry; Deborah McCurdy; Marissa Klein-Gitelman; Carol Wallace; Richard Silver; Linda Wagner-Weiner; Gloria C Higgins; Hermine I Brunner; Lawrence Jung; Jennifer B Soep; Ann Reed
Journal:  Arthritis Rheum       Date:  2009-05

Review 4.  Adiponectin and inflammation: consensus and controversy.

Authors:  Giamila Fantuzzi
Journal:  J Allergy Clin Immunol       Date:  2007-12-03       Impact factor: 10.793

Review 5.  Adiponectin and cardiovascular disease.

Authors:  Rei Shibata; Noriyuki Ouchi; Toyoaki Murohara
Journal:  Circ J       Date:  2009-03-03       Impact factor: 2.993

6.  Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.

Authors:  Maureen McMahon; Jennifer Grossman; Brian Skaggs; John Fitzgerald; Lori Sahakian; Nagesh Ragavendra; Christina Charles-Schoeman; Karol Watson; Weng Kee Wong; Elizabeth Volkmann; Weiling Chen; Alan Gorn; George Karpouzas; Michael Weisman; Daniel J Wallace; Bevra H Hahn
Journal:  Arthritis Rheum       Date:  2009-08

7.  Metabolic abnormalities and cardiovascular risk factors in children with myositis.

Authors:  Kathleen Coyle; Kristina I Rother; Martina Weise; Alaa Ahmed; Frederick W Miller; Lisa G Rider
Journal:  J Pediatr       Date:  2009-07-29       Impact factor: 4.406

8.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

Authors:  K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

9.  Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

Authors:  Stéphanie Christen-Zaech; Roopa Seshadri; Joyce Sundberg; Amy S Paller; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02

Review 10.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.

Authors:  Jeff S Isenberg; Gema Martin-Manso; Justin B Maxhimer; David D Roberts
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

View more
  21 in total

Review 1.  A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.

Authors:  Liza J McCann; Clare E Pain
Journal:  Indian J Pediatr       Date:  2016-02       Impact factor: 1.967

2.  Decreased flow-mediated dilatation with increased arterial stiffness and thickness as early signs of atherosclerosis in polymyositis and dermatomyositis patients.

Authors:  Melinda Vincze; H Dér; Gy Kerekes; P Szodoray; M Zeher; K Dankó; P Soltész
Journal:  Clin Rheumatol       Date:  2014-03-12       Impact factor: 2.980

Review 3.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

4.  Inflammatory myopathies: One-center experience.

Authors:  Metin Işık; Şule Bilgen; İsmail Doğan; Levent Kılıç
Journal:  Eur J Rheumatol       Date:  2014-09-01

5.  Long-term outcomes in Juvenile Myositis patients.

Authors:  Vladislav Tsaltskan; Annette Aldous; Sam Serafi; Anna Yakovleva; Heidi Sami; Gulnara Mamyrova; Ira N Targoff; Adam Schiffenbauer; Frederick W Miller; Samuel J Simmens; Rodolfo Curiel; Olcay Y Jones; Lisa G Rider
Journal:  Semin Arthritis Rheum       Date:  2019-06-28       Impact factor: 5.532

6.  Methylation alterations of WT1 and homeobox genes in inflamed muscle biopsy samples from patients with untreated juvenile dermatomyositis suggest self-renewal capacity.

Authors:  Min Wang; Hehuang Xie; Sheela Shrestha; Simone Sredni; Gabrielle A Morgan; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2012-10

Review 7.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 8.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

9.  Serum levels of adipokines in patients with idiopathic inflammatory myopathies: a pilot study.

Authors:  Javier Loaiza-Félix; Mariana Moreno-Ramírez; F Luis Pérez-García; Valentín Jiménez-Rojas; Fausto Sánchez-Muñoz; M Luis Amezcua-Guerra
Journal:  Rheumatol Int       Date:  2017-05-23       Impact factor: 3.580

Review 10.  Cardiovascular risk in pediatric-onset rheumatological diseases.

Authors:  Julie Barsalou; Timothy J Bradley; Earl D Silverman
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.